Lineage Cell Therapeutics Provides Update on OpRegen

Lineage Cell Therapeutics provided an update on its progress with OpRegen (RG6501), its product candidate for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Lineage stated that it continues to execute its collaboration with Roche and Genentech across multiple functional areas, including support for the ongoing phase 2a multicenter clinical study in patients with GA secondary to AMD. Among the updates, the company announced:

• Additional sites expected to come online this year for the phase 2a study
• Preliminary evidence of durable anatomical and functional improvements following administration of OpRegen cells from the phase 1/2a clinical study was presented at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and other medical and scientific meetings, including durable improvement observed in one patient with long-term follow-up available (4 years).